Algert Global LLC acquired a new stake in Catalent Inc (NASDAQ:CTLT) during the second quarter, Holdings Channel reports. The fund acquired 30,155 shares of the company’s stock, valued at approximately $1,058,000.

Several other institutional investors have also modified their holdings of CTLT. Massachusetts Financial Services Co. MA boosted its position in shares of Catalent by 1.2% in the first quarter. Massachusetts Financial Services Co. MA now owns 10,909 shares of the company’s stock valued at $309,000 after buying an additional 130 shares during the period. Aperio Group LLC boosted its position in shares of Catalent by 0.8% in the second quarter. Aperio Group LLC now owns 23,088 shares of the company’s stock valued at $810,000 after buying an additional 190 shares during the period. Capstone Asset Management Co. boosted its position in shares of Catalent by 2.3% in the second quarter. Capstone Asset Management Co. now owns 10,130 shares of the company’s stock valued at $356,000 after buying an additional 230 shares during the period. Forward Management LLC boosted its position in shares of Catalent by 6.6% in the first quarter. Forward Management LLC now owns 5,844 shares of the company’s stock valued at $166,000 after buying an additional 363 shares during the period. Finally, Advantus Capital Management Inc boosted its position in shares of Catalent by 3.0% in the first quarter. Advantus Capital Management Inc now owns 15,972 shares of the company’s stock valued at $452,000 after buying an additional 468 shares during the period.

Shares of Catalent Inc (NASDAQ CTLT) opened at 34.48 on Thursday. Catalent Inc has a 1-year low of $21.83 and a 1-year high of $38.73. The company has a market cap of $4.31 billion and a PE ratio of 40.61. The firm’s 50-day moving average is $35.58 and its 200-day moving average is $31.76.

COPYRIGHT VIOLATION NOTICE: “Algert Global LLC Acquires New Position in Catalent Inc (NASDAQ:CTLT)” was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://www.watchlistnews.com/algert-global-llc-acquires-new-position-in-catalent-inc-nasdaqctlt/1469053.html.

Several equities analysts have recently weighed in on the stock. William Blair upgraded shares of Catalent from a “market perform” rating to an “outperform” rating in a research note on Friday, May 5th. Bank of America Corporation reiterated a “buy” rating and issued a $38.00 price objective (up previously from $37.00) on shares of Catalent in a research note on Friday, July 21st. BidaskClub cut shares of Catalent from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Zacks Investment Research upgraded shares of Catalent from a “sell” rating to a “buy” rating and set a $39.00 price objective on the stock in a research note on Tuesday, July 4th. Finally, TheStreet upgraded shares of Catalent from a “c” rating to a “b-” rating in a research note on Wednesday, April 19th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the company’s stock. Catalent currently has a consensus rating of “Buy” and an average price target of $32.00.

In other Catalent news, SVP Christine Dolan sold 745 shares of the business’s stock in a transaction that occurred on Tuesday, August 1st. The stock was sold at an average price of $34.85, for a total value of $25,963.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Catalent Company Profile

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.

Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent Inc (NASDAQ:CTLT).

Institutional Ownership by Quarter for Catalent (NASDAQ:CTLT)

Receive News & Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.